Product Development


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1ef7l320d0">GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute</h1><h2 class="title-bottom" doc-editable="title" data-component-id="doc-1ef7l34r60">Plus SAB gets additional funding from U.S. government, starts human trials</h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1ef7l3fol0">
    <span class="ng-tns-c17-4" doc-editable="text">By Sandi Wong, Assistant Editor</span>
</div><div class="date" data-component-id="doc-1ef7l3l440">
  <span class="byline" doc-editable="text"></span>
</div></div></div></div>


SAB Biotherapeutics Inc.

GigaGen Inc.

Infectious

Coronavirus disease (COVID-19)

cov19sci

cov19count

SAB-185

GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute

Plus SAB gets additional funding from U.S. government, starts human trials

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>